Global Cervical Cancer Diagnostic Testing Market 2022-2028

117 pages, November 2018
About this market
With the growth in geriatric population worldwide, the increasing age plays a significant prognostic role in the development of cervical cancer. According to the US Census Bureau, the global geriatric population (65 years and above) is expected to exceed 1.5 billion by 2050, making it approximately 16% of the total world's population. For instance, according to the CDC, in 2015, there were 1,171 cases of cervical cancer among women aged 60-64 years in the US alone. Due to the lack of early detection, several elderly women aged 65 years and above are more likely to die due to their advanced stage at diagnosis. Nevertheless, with adequate awareness and education programs, the misperception about the disease can be reduced. This will result in the higher adoption of screening, thereby leading to the increased use of diagnostic kits. Analysts have predicted that the cervical cancer diagnostic testing market will register a CAGR of more than 6% by 2023.
Market Overview
Increased adoption of HPV home testing kits
Several large companies are focused on R&D of new and innovative products that can provide accurate and instant test results at home and cut down cost burden on the patients on management of cervical cancer. In addition, the rising awareness on the importance of cervical cancer screen on time will fuel the demand for cervical cancer diagnostic market during the next five years.
Varying screening policies
The recommended screening policies for cervical cancer usually vary in different countries. Although certain professional societies and organizations have developed guidelines, efforts are needed for their uniform implementation. The difference in the target age can lead to shortcomings in terms of routine registration for the screening program, evaluation, and monitoring, which can negatively impact the adoption of cervical cancer diagnostic testing.
For the detailed list of factors that will drive and challenge the growth of the cervical cancer diagnostic testing market during the 2019-2023 period, view our report.
Competitive Landscape
The market appears to be quite fragmented but will become highly concentrated with the presence of a few companies including Abbott Laboratories and BD, the competitive environment is very intense. Factors such as the growth in geriatric population and increased adoption of HPV home testing kits, will provide considerable growth opportunities to cervical cancer diagnostic testing vendors. Abbott Laboratories, BD, F. Hoffmann-La Roche, Hologic, and QIAGEN are some of the major companies covered in this report.

Frequently Asked Questions



This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

  • By product type
  • By End User/Applications
  • By Technology
  • By Region

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Please Select a Format

market Reports market Reports